Cliff Asness's LGND Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 4,584 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $812,010, representing 0.00% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in LGND, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2019, adding 135,286 shares. Largest reduction occurred in Q2 2020, reducing 130,394 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +12,980 | Add 0.00% | 12,979 | $20.73 |
| Q2 2013 | +12,980 | Add 0.00% | 12,979 | $37.45 |
| Q4 2013 | +7,898 | Add 60.85% | 20,877 | $52.59 |
| Q1 2014 | +2,500 | Add 11.97% | 23,377 | $67.25 |
| Q2 2014 | -100 | Reduce 0.43% | 23,277 | $62.29 |
| Q3 2014 | -2,700 | Reduce 11.60% | 20,577 | $46.99 |
| Q4 2014 | -20,577 | Sold Out | 20,577 | $0.00 |
| Q2 2015 | +7,529 | New Buy | 7,529 | $100.94 |
| Q3 2015 | +5,047 | Add 67.03% | 12,576 | $85.64 |
| Q4 2015 | +7,028 | Add 55.88% | 19,604 | $108.45 |
| Q1 2016 | +16,400 | Add 83.66% | 36,004 | $107.10 |
| Q2 2016 | -6,991 | Reduce 19.42% | 29,013 | $119.26 |
| Q3 2016 | -2,953 | Reduce 10.18% | 26,060 | $102.07 |
| Q4 2016 | -18,310 | Reduce 70.26% | 7,750 | $101.55 |
| Q1 2017 | -7,750 | Sold Out | 7,750 | $0.00 |
| Q3 2017 | +7,850 | New Buy | 7,850 | $136.18 |
| Q4 2017 | +7,312 | Add 93.15% | 15,162 | $136.92 |
| Q1 2018 | +2,742 | Add 18.08% | 17,904 | $165.16 |
| Q2 2018 | +2,599 | Add 14.52% | 20,503 | $207.19 |
| Q3 2018 | +5,517 | Add 26.91% | 26,020 | $274.48 |
| Q4 2018 | +37,045 | Add 142.37% | 63,065 | $135.70 |
| Q1 2019 | +13,835 | Add 21.94% | 76,900 | $125.71 |
| Q2 2019 | +49,166 | Add 63.93% | 126,066 | $114.15 |
| Q3 2019 | +135,286 | Add 107.31% | 261,352 | $99.54 |
| Q4 2019 | -54,517 | Reduce 20.86% | 206,835 | $104.29 |
| Q1 2020 | -32,632 | Reduce 15.78% | 174,203 | $72.72 |
| Q2 2020 | -130,394 | Reduce 74.85% | 43,809 | $111.85 |
| Q3 2020 | -18,077 | Reduce 41.26% | 25,732 | $95.33 |
| Q4 2020 | +2,717 | Add 10.56% | 28,449 | $99.44 |
| Q1 2021 | -22,977 | Reduce 80.77% | 5,472 | $152.41 |
| Q2 2021 | +7,462 | Add 136.37% | 12,934 | $131.20 |
| Q3 2021 | -9,404 | Reduce 72.71% | 3,530 | $139.38 |
| Q4 2021 | -1,314 | Reduce 37.22% | 2,216 | $154.33 |
| Q1 2022 | +5,435 | Add 245.26% | 7,651 | $112.53 |
| Q2 2022 | +9,962 | Add 130.21% | 17,613 | $86.75 |
| Q3 2022 | +11,026 | Add 62.60% | 28,639 | $86.11 |
| Q4 2022 | +2,469 | Add 8.62% | 31,108 | $66.02 |
| Q1 2023 | +21,416 | Add 68.84% | 52,524 | $72.28 |
| Q2 2023 | -4,255 | Reduce 8.10% | 48,269 | $72.10 |
| Q3 2023 | +12,918 | Add 26.76% | 61,187 | $59.92 |
| Q4 2023 | -8,061 | Reduce 13.17% | 53,126 | $71.42 |
| Q1 2024 | -30,561 | Reduce 57.53% | 22,565 | $71.94 |
| Q2 2024 | -17,641 | Reduce 78.18% | 4,924 | $82.72 |
| Q3 2024 | -4,924 | Sold Out | 4,924 | $0.00 |
| Q1 2025 | +3,335 | New Buy | 3,335 | $103.06 |
| Q2 2025 | +23 | Add 0.69% | 3,358 | $113.68 |
| Q3 2025 | +1,226 | Add 36.51% | 4,584 | $177.14 |
Cliff Asness's Ligand Pharmaceuticals Incorporated Investment FAQs
Cliff Asness first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q4 2012, acquiring 12,979 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Ligand Pharmaceuticals Incorporated (LGND) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q3 2019, adding 261,352 shares worth $26.02 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 4,584 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $812,010. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 261,352 shares, as reported at the end of Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.